Operative complications, residual varices, recurrence of varices bleeding and encephalopathy were observed. Results: Two groups were not dead cases, encephalopathy cases and recurrence cases of varices bleeding in the duration of hospital stay. Sugiura group had 4 cases of digestive tract leakage and 2 cases of esophageal stricture relating with stapler transaction. Sugiura group and Hassab group had 4 and 3 portal vein thrombosis cases respectively (P > 0.05). At the first year of post-operation, residual varices rate was 21.3% in Sugiura group and 50% in Hassab group (P < 0.05), and recurrent rate of varices bleeding was 0 in Sugiura group and 10.3% in Hassab group (P < 0.05). Conclusion: The modified Sugiura procedure has a good effect in treating varices bleeding. It is better than the Hassab procedure in diminishing residual varices and preventing recurrence of varices bleeding. Results: Obtained data show a high level of CK-18 in patients with acute alcoholic hepatitis with cholestasis (967.11 ± 111.20 U/L) and without cholestasis (1091.67 ± 153.30 U/L; 40% < P < 50%). Serum ALT activity in alcohol surrogate users was significantly higher (169.57 ± 47.54 U/L) than in patients who used qualitative ethanol (33.62 ± 3.27 U/L; 99% < P < 99.9%). Serum C-reactive protein level was significantly higher in patients without cholestasis (42.27 ± 6.79 mg/L) than in patients with cholestasis (27.13 ± 9.24 mg/L; P > 99.9%). Hyaluronic acid concentration was very high in sera of patients with acute alcoholic hepatitis without cholestasis (1006.46 ± 56.96 ng/ml) if compared with cholestatic acute alcoholic hepatitis (271.67 ± 44.33 ng/ml; P > 99.9%). Conclusion: Liver cell death in acute alcoholic hepatitis is partially due to necrosis, but there is evidence that apoptosis plays an important role in development of cell injury. The extent of apoptosis process in clinical practice usually is underestimated. Background and Aim: We use model for end-stage liver disease (MELD) scoring system to predict 3-month prognosis of patients with acute-on-chronic liver failure (ACLF) after plasma exchange (PE) and lamivudine treatment and study the predictive factors on the prognosis of patients. Methods: 280 patients treated with lamivudine were randomly divided into PE and control groups. The relationship of mortality and influential factors of patients were studied by univariate and multivariate analysis. Results: The mortality (49.4%) of patients in PE group with MELD score from 30 to 40 was lower than that (86.1%) of control group (c 2 = 24.546, P < 0.01). TBIL rebound rate of dead group was significantly higher than that of survival group (P < 0.01). Univariate analysis showed that mortality was significantly related to age (P = 0.003), treatment method (P = 0.000), TBIL (P = 0.010), MELD score (P = 0.001), INR (P = 0.014), pretreatment HBV DNA load (P = 0.000), decline of HBV DNA load during therapy (P = 0.013), encephalopathy (P = 0.019) and hepatorenal syndrome (P = 0.026). In multivariate analysis, in patients with MELD scores 30 40, treatment method (P = 0.003), pretreatment HBV DNA load (P = 0.009), decline of HBV DNA load during therapy (P = 0.016) and encephalopathy (P = 0.015) were independent predictors of mortality; for MELD scores above 40, only MELD score (P = 0.012) was independent predictive. Conclusions: PE significantly decreases the mortality of patients with MELD score 30 40. For ACLF patients with MELD score 30 40, a low viral load pre-treatment and quick decline of HBV DNA load are good predictors for the survival of PE and lamivudine treatment.
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